人干扰素α1b雾化吸入联合常规治疗对低龄呼吸道合胞病毒感染肺炎患儿的效果分析

doi:10.3969/j.issn.1001-8131.2025.05.013

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (481 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application effect of human interferon α1b(IFN-α1b) aerosol inhalation combined with conventional therapy for young children with respiratory syncytial virus(RSV)-infected pneumonia. Methods A total of 82 children with RSV-infected pneumonia were randomLy selected as research samples and randomLy separated into two groups according to the digital table method.The conventional group adopted conventional treatment,and the aerosol group was treated with IFN-α1b aerosol inhalation on the basis of conventional treatment.The clinical efficacy,duration of symptom subsidence,time required for white blood cell count to return to normal,length of hospital stay,C-reactive protein(CRP) and incidence of adverse reactions between the two groups were compared. Results The clinical efficacy of the nebulizer group was higher than that of the conventional group,and the duration of symptom subsidence,the time required for the white blood cell count to return to normal,and the length of hospital stay were all lower than those of the conventional group(P<0.05).After 6 days of treatment,the CRP level of the nebulizer group was also lower than that of the conventional group(P<0.05).No notable disparity was observed in the occurrence of adverse reactions between the two groups(P>0.05). Conclusion IFN-α1b nebulizer inhalation can effectively relieve symptoms,improve inflammatory status,and has high safety,which can provide a reference for the formulation of treatment strategies for children with RSV-infected pneumonia in clinical practice.

Key words： Pneumonia Respiratory Syncytial Virus Human Interferon α1b Aerosol Inhalation

Received: 28 April 2025

PACS:

R720.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Hou Shuangshuang
	Qin Huijuan
	Zhang Xiaoxiao

Cite this article:

Hou Shuangshuang,Qin Huijuan,Zhang Xiaoxiao. Analysis of the Effect of Human Interferon α1b Aerosol Inhalation Combined with Conventional Treatment on Young Children with Respiratory Syncytial Virus Infection Pneumonia[J]. journal1, 2025, 45(5): 41-43.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2025.05.013 OR http://www.hrbyybjb.org.cn/EN/Y2025/V45/I5/41

[1] 黄晓文,庞珍珍,周斐斐,等.2018~2023年杭州市儿童呼吸道合胞病毒感染流行特征[J].中华医院感染学杂志,2024,34(6):907-911.
[2] 任康轶,任洛,邓昱,等.2013~2018年重庆地区2066例急性下呼吸道感染住院患儿呼吸道合胞病毒流行特征分析[J].中国当代儿科杂志,2021,23(01):67-73.
[3] 蔡莹. 重组人干扰素α1b雾化吸入在儿科病毒感染呼吸道疾病治疗中的临床应用[J].北方药学,2021,18(5):135-136.
[4] 张垚,孙新,张国成.不同剂量重组人干扰素α1b雾化吸入治疗儿童流行性感冒疗效观察[J].海南医学,2020,31(4):466-469.
[5] 中华医学会儿科学分会呼吸学组,中华儿科杂志编辑委员会,中国医药教育协会儿科专业委员会.儿童社区获得性肺炎管理指南(2024修订)[J].中华儿科杂志,2024,62(10):920-930.
[6] 刘连凤,史军然,薛红霞,等.重组人干扰素α1b雾化吸入治疗儿童上呼吸道病毒感染及预防儿童上呼吸道病毒感染诱发毛细支气管炎效果研究[J].临床误诊误治,2019,32(5):24-29.
[7] 刘小会,徐保平,尚云晓,等.雾化吸入重组人干扰素α1b治疗小儿呼吸道合胞病毒下呼吸道感染的有效性和安全性多中心、随机、双盲、安慰剂对照Ⅲ期临床研究[J].中华实用儿科临床杂志,2025,40(3):180-186.
[8] 徐炯炯,吴安娜,倪舒芹.重组人干扰素治疗儿童呼吸道合胞病毒感染的临床疗效[J].中华医院感染学杂志,2019,29(18):2861-2864,2868.
[9] 吴越,陈启庭,张交生,等.超说明书使用注射用重组人干扰素α1b雾化吸入治疗儿童病毒性上呼吸道感染的临床研究[J].海峡药学,2020,32(7):172-173.
[10] 陈霞,韩瑛.重组人干扰素α1b雾化吸入辅助治疗儿童上呼吸道感染的效果[J].妇儿健康导刊,2024,3(1):62-64,68.
[11] 杨曾贻. 干扰素α1b联合布地奈德与沙丁胺醇雾化治疗小儿喘息性支气管肺炎的临床效果[J].临床合理用药,2024,17(32):127-129.
[12] 石佳利,张茜茜.注射用人干扰素α1b联合布地奈德吸入治疗小儿肺炎的临床疗效及安全性分析[J].四川生理科学杂志,2024,46(8):1825-1827.
[13] 范建荣,毕研龙,范铭兴,等.热毒宁联合雾化重组人干扰素α1b对儿童呼吸道合胞病毒感染肺炎的疗效及免疫功能影响[J].中华中医药学刊,2021,39(11):189-192.
[14] 刘新锋,刘晓娟,赵志妙,等.布地奈德雾化吸入治疗婴幼儿吸入性肺炎的效果及对IL-6、IL-8、TNF-α的影响[J].河北医药,2020,42(19):2961-2963,2967.
[15] 吴文忠. 小儿肺热咳喘口服液联合重组人干扰素α1b雾化吸入对呼吸道合胞病毒肺炎患儿T细胞亚群和炎性因子的影响[J].现代生物医学进展,2022,22(8):1470-1474.